Combo drug for early Parkinson’s set to improve treatment
Phase III studies of Pharma Two B’s once-daily pill delivers the best aspects of two existing drugs for superior efficacy and safety.
Phase III studies of Pharma Two B’s once-daily pill delivers the best aspects of two existing drugs for superior efficacy and safety.
Voluntary healthcare service provider opens a unique recovery and wellness center where women receive emotional support following the trauma of newborn death.
Technion study finds that a disruption in the protein clearance mechanism in the brain allows for toxins to accumulate, triggering the illness.
Results are staggering, says expert who led study at Israel hospital.
To honor World Sight Day, October 12, ISRAEL21c brings you a summary of innovative blue-and-white solutions.
The Ebola virus under a microscope. Photo by Nixx Photography via Shutterstock.com
Designing for daylight in patient rooms could improve health outcomes, say researchers.
Why do cancer cells often bypass the immune system’s gatekeeper? New study finds a possible answer in cellular waste-processing machinery.
It weighs just 20 grams, is worn like a wristband, and inflates a foil balloon with 8 liters of hydrogen foam to keep a swimmer afloat.
AI analysis of CT scans led to earlier detection of intracerebral hemorrhage, enabling physicians to begin therapeutic interventions quickly.
Getting its inspiration from nature, a medical-device company is developing a less invasive way to oxygenate blood without mechanical ventilation. It’s a vital step forward.
Newest service from Belong.Life provides automated solution for cancer clinical trial matching and recruitment.
Retrospective study of embryos chosen for implantation reveals that automated tool can help find the hardiest ones.
Shoulder dystocia occurs in 1.5 million births each year, often leading to permanent injury. An Israeli OB/GYN’s simple device could be the answer.
What’s best to eat before and after a full-day fast? Does fasting hurt or help our bodies? Who shouldn’t fast? We’ve got your answers.